MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 38.63Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 74.18です。
割高
同社の最新のPEは-3.59で、過去3年間の水準と比較して高値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は78.80M株で、前四半期比で19.12%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を5.60M株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は0.71です。